Akademik Veri Yönetim Sistemi
Journal of Medical Archives, sa.1, ss.1-5, 2022 (Hakemli Dergi)
Abstract
Objective: To examine the point where the insulin drug has come so far throughout its historical development and to
gather the pharmacology of the insulin drug under one roof.
Material and Methods: No humans or animals were used in this study. In this study, existing articles on the pharmacology
of insulin were evaluated by examining the PubMed database.
Results: There is no data to present in this study.
Conclusion: Considering its historical background; insulin is constantly evolving. Insulin is normally released from
pancreatic beta cells at a low basal rate. Insulin is a molecule with an anabolic effect and in addition to glucose; it also
ensures that fats and amino acids are taken into the cell used and stored. The insulin receptor consists of two heterodimers,
alpha and beta subunits, which are covalently linked. The absorption of insulin into the bloodstream after subcutaneous
absorption is the rate-limiting step of insulin activity. The two main organs that remove insulin from the circulation, which
have a half-life of approximately 3-5 minutes, are the liver and kidney. The production and development of analogues for
human insulin have been thanks to recombinant-DNA technology. Recently, a new inhaled insulin powder product
(Afrezza) has entered the market. A dry powder formulation of regular human insulin (technosphere insulin, Afrezza)
is approved for use in adults with diabetes. In addition to this short review of insulin, more should be said about this
drug in the future